Study Reveals Metabolic Vulnerability in High-Risk MDS Stem Cells
Researchers at the University of Colorado Anschutz Cancer Center have uncovered a previously unknown metabolic vulnerability in the stem cells responsible for high-risk myelodysplastic syndromes (MDS). This finding could eventually aid in developing treatments that more precisely target the cells driving this aggressive blood cancer. The study, published in Blood Cancer Discovery, reveals that high-risk MDS stem cells depend unusually heavily on nicotinamide adenine dinucleotide (NAD), a crucial molecule in cellular energy production. When researchers disrupted the pathway that maintains NAD levels, they were able to selectively weaken the disease-driving stem cells, while healthy blood-forming stem cells demonstrated greater adaptability. Eric M. Pietras, PhD, an associate professor in the Division of Hematology at the University of Colorado Anschutz and co-lead author of the study, stated, "What we found is that these cells actually use energy in different ways than normal stem cells do. They were relying on a specific set of proteins and processes that created a vulnerability we could potentially target." Myelodysplastic syndromes are blood cancers that hinder the bone marrow's ability to produce healthy blood cells, leading to severe anemia, frequent infections, and the need for repeated blood transfusions. High-risk MDS can also progress to acute myeloid leukemia (AML), a challenging form of leukemia to treat. The condition primarily affects older adults, with an estimated 10,000 to 20,000 new diagnoses in the United States each year. The researchers aimed to identify biological differences between cancer stem cells and their healthy counterparts. Their experiments indicated that MDS stem cells rely heavily on the NAD salvage pathway, a recycling process that maintains NAD supply. One enzyme in this pathway, nicotinamide phosphoribosyltransferase (NAMPT), emerged as a potential treatment target. Pietras noted, "These cells had developed a much greater need for this resource. They appear to use NAD at a much higher rate than normal cells, which creates a vulnerability that we can exploit with new types of drugs." The researchers characterize this dependence as an "energy addiction." Healthy blood-forming stem cells can adapt their energy production methods when conditions change, but MDS stem cells show significantly less flexibility. When NAMPT was blocked, NAD levels decreased, leading to an energy crisis in the cancer stem cells, thereby selectively weakening the cells responsible for the disease. Experiments using patient-derived MDS cells and animal models demonstrated that interfering with NAD metabolism reduced the number of disease-driving stem cells. The researchers plan to investigate drugs targeting NAMPT in clinical studies involving individuals with MDS and related blood cancers. Pietras emphasized, "Our goal is to identify approaches that make these complex diseases more treatable by finding the differences between cancer cells and normal cells. If we can understand those differences, we can begin to develop therapies that are more precise and more effective for patients." Dr. Pietras and Dr. Craig T. Jordan are co-lead authors of the study, which involved contributions from Sweta B. Patel, PhD, and other researchers at the University of Colorado Anschutz, as well as collaborators from various institutions. The research received support from the National Institutes of Health, the Edward P. Evans Foundation, Blood Cancer United, and other partners dedicated to advancing blood cancer research.




